August 5, 2024AddictionOpen Access

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients

View Full Paper

Ask AI

Bookmark

Real-world effectiveness was evaluated to compare extended-release naltrexone against sublingual buprenorphine for the clinical management of patients diagnosed with opioid use disorder.
Both extended-release naltrexone and sublingual buprenorphine maintain regulatory approval for administering opioid use disorder therapy across diverse outpatient medical environments.
Assessing comparative effectiveness in Medicaid populations highlights real-world treatment choices, informing healthcare delivery decisions for individuals facing opioid use disorder.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Comparative effectiveness research reports real-world outcomes of extended-release naltrexone and sublingual buprenorphine in Medicaid recipients, highlighting clinical care options.

Cite This Study

Ross et al. (2024) studied this question.

synapsesocial.com/papers/68e5d588b6db64358756bcbd https://doi.org/10.1111/add.16630

View Full Paper

Ask AI

Bookmark

Implication

Comparative effectiveness research reports real-world outcomes of extended-release naltrexone and sublingual buprenorphine in Medicaid recipients, highlighting clinical care options.

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients

Key Points

Discussion

Implication

Cite This Study

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider